Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing α-Galactosidase A

Fabry disease is a rare X-linked disorder affecting α-galactosidase A, a rate-limiting enzyme in lysosomal catabolism of glycosphingolipids. Current treatments present important limitations, such as low half-life and limited distribution, which gene therapy can overcome. The aim of this work was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Biferi, Maria Grazia, Cohen-Tannoudji, Mathilde, García-Silva, Andrea, Souto-Rodríguez, Olga, Viéitez-González, Irene, San-Millán-Tejado, Beatriz, Fernández-Carrera, Andrea, Pérez-Márquez, Tania, Teijeira-Bautista, Susana, Barrera, Soraya, Domínguez, Vanesa, Marais, Thibaut, González-Fernández, África, Barkats, Martine, Ortolano, Saida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725667/
https://www.ncbi.nlm.nih.gov/pubmed/33335943
http://dx.doi.org/10.1016/j.omtm.2020.10.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725667/
https://www.ncbi.nlm.nih.gov/pubmed/33335943
http://dx.doi.org/10.1016/j.omtm.2020.10.016

Ejemplares similares